This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher is speaking on “Balancing cost effectiveness with economics – alleviate funding constraints on HTA approved drugs by managing diverging stakeholder perspectives.” CRA is also sponsoring the conference.
For more information on the event, click here.
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.
As part of the CRA Life Sciences series on leveraging RADAR, our orphan drug data repository, we analyzed the relationship between annual list prices achieved
The U.S. Most Favored Nation (MFN) Executive Order could upend global drug pricing as we know it. Some manufacturers are now vowing to launch only at U.S....
CRA is a proud sponsor of the event, back for its 8th edition. This half-day, high-impact conference brings together top arbitrators, counsel, experts and...
